Compare PNFP & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNFP | DVA |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 8.2B |
| IPO Year | N/A | 1995 |
| Metric | PNFP | DVA |
|---|---|---|
| Price | $95.86 | $105.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 4 |
| Target Price | $111.79 | ★ $145.00 |
| AVG Volume (30 Days) | ★ 2.2M | 838.2K |
| Earning Date | 01-21-2026 | 02-02-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 35.40 | 5.63 |
| EPS | 8.07 | ★ 9.76 |
| Revenue | $1,947,606,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | $160.52 | $6.50 |
| Revenue Next Year | $8.18 | $2.97 |
| P/E Ratio | $11.88 | ★ $11.01 |
| Revenue Growth | ★ 20.51 | 5.14 |
| 52 Week Low | $81.57 | $101.00 |
| 52 Week High | $127.85 | $179.60 |
| Indicator | PNFP | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 46.68 | 38.33 |
| Support Level | $94.30 | $103.48 |
| Resistance Level | $107.00 | $110.43 |
| Average True Range (ATR) | 3.33 | 3.12 |
| MACD | -0.28 | 0.17 |
| Stochastic Oscillator | 18.38 | 35.94 |
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.